After the discovery of anti-aquaporin-4 (AQP4) antibody (Ab) in neuromyelitis optica
(NMO) and related disorders, the diagnosis and treatment in NMO has dramatically changed
with unique pathomechanism of autoimmune astrocytopathy distinct from multiple sclerosis
(MS). Moreover, in AQP4-Ab negative cases, there are various types of disseminated
encephalomyelitis (DEM), often misdiagnosed as classical MS, such as tumefactive disease,
Balo’ disease and acute DEM. Now it was revealed that anti-myelin oligodendrocyte
glycoprotein (MOG) Ab were found in about half of ADEM cases especially in paediatric
cases. The role of this antibody has long been controversial because of non-specific
detection in previous studies, but now specific antibody against conformational epitope
of extracellular domain is considered as pathogenic antibody. There were some cases
of anti-MOG-Ab positive opticomyelitis with bilateral optic neuritis and long spinal
cord lesions, like monophasic Devic’s NMO disease. However, the clear difference of
anti-MOG-Ab syndrome from anti-AQP4-ab syndrome is the lack of elevated CSF GFAP and
the relatively mild prognosis. In adult MOG-positive cases, there are some cases of
unique cortical encephalitis with epileptic seizure revealed in our cohort study.
The specific features including unilateral cerebral cortical FLAIR hyper-intense lesions,
which were swollen and hyper-perfused on SPECT. In pathology, there are diffuse inflammatory
lesions at the cortical meningeal areas with dominant loss of MOG, but other myelin
and AQP4, suggesting MOG spectrum. Until now, there have been several kinds of DEM
with unknown etiology probably distinct from MS, which is promising to clarify each
specific pathomechanism in near future.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect